<div id="readability-page-1"><h3>Memorial Day Sale – Claim 70% Off TipRanks</h3><ul><li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. </li><li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter </li></ul>An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available. CSPC Pharmaceutical Group reported that shareholders at its annual general meeting on 28 May 2026 approved all ordinary resolutions, including receipt of the 2025 audited financial statements and a final dividend of HK15 cents per share. Investors also backed the re-election of executive and independent non-executive directors, the reappointment of Deloitte Touche Tohmatsu as auditor, share buyback and issuance mandates, and adoption of a new share option scheme, though some board and auditor items drew notable minority opposition. In addition, shareholders passed a special resolution to adopt new Articles of Association, signaling governance and structural updates aligned with the company’s evolving needs. The broad endorsement of management proposals, combined with refreshed incentive and capital management tools, reinforces the board’s authority and flexibility in steering future strategy, while the pockets of dissent highlight ongoing investor scrutiny over board composition and audit oversight. The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page. More about CSPC Pharmaceutical Group CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company listed on the Hong Kong Stock Exchange. It operates in the healthcare and drug manufacturing industry, focusing on the development, production and sale of pharmaceutical products for domestic and international markets. Average Trading Volume: 88,371,599 Technical Sentiment Signal: Hold Current Market Cap: HK$85.58B </div>

01093

562050

159506

CSPC Pharmaceutical Group's shareholders approved all resolutions at the AGM on May 28, 2026, including the 2025 audited financial statements and a final dividend of HK15 cents per share. The re-election of directors and the reappointment of Deloitte as auditor were also supported, despite some opposition. A special resolution to adopt new Articles of Association was passed, reflecting governance updates. The stock has a Buy rating with a target price of HK$13.05.

Tip Ranks

CSPC PHARMA

Hwabao WP CSI Pharmaceuticals ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

CSPC Pharmaceutical Wins Shareholder Backing for All AGM Resolutions